Zimmer Biomet Holdings (ZBH) Misses Q4 EPS by 3c, Offers Guidance

Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $1.95, $0.03 worse than the analyst estimate of $1.98. Revenue for the quarter came in at $2.04 billion versus the consensus estimate of $2.07 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2022 EPS of $6.40-$6.80 vs 7.93 consensus.

• 2022 Reported Revenue Change (4.0)% - 0.0%

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• BofA lists top 5 themes driving next $1tn in incremental semi sales